Lupin Ltd. Hits New 52-Week High of Rs.2261.95 on 17 Feb 2026

Stock Performance and Market Context

On 17 Feb 2026, Lupin Ltd. outperformed its sector peers by 0.71%, closing at its highest level in the past 52 weeks. The stock has recorded gains for two consecutive days, delivering a cumulative return of 2.18% during this period. Trading above all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — the stock’s technical indicators signal strong upward momentum.

In comparison, the Sensex opened flat but gradually gained 0.14% to trade at 83,390.27, remaining 3.32% below its own 52-week high of 86,159.02. While the Sensex is currently trading below its 50-day moving average, Lupin’s outperformance highlights its relative strength within the broader market environment. Mega-cap stocks are leading the market gains today, yet Lupin’s mid-cap status has not hindered its impressive run.

Over the past year, Lupin Ltd. has delivered a total return of 10.66%, marginally outperforming the Sensex’s 9.64% return. The stock’s 52-week low was Rs.1774, indicating a substantial appreciation of nearly 27.5% from that level to today’s new high.

Financial Metrics Underpinning the Rally

Lupin Ltd.’s financial fundamentals have been a key driver behind the stock’s upward trajectory. The company maintains a low average debt-to-equity ratio of 0.10 times, reflecting a conservative capital structure that supports sustainable growth. Net sales have expanded at an annualised rate of 11.42%, while operating profit margins stand robustly at 33.60%, indicating efficient cost management and strong operational performance.

Recent quarterly results have been positive for three consecutive quarters, with the latest half-yearly return on capital employed (ROCE) reaching a peak of 22.22%. Profit before tax excluding other income (PBT less OI) for the most recent quarter was Rs.1,833.91 crores, marking a significant 43.6% increase compared to the previous four-quarter average. Net sales for the quarter also hit a record high of Rs.7,167.52 crores.

The company’s return on equity (ROE) stands at an attractive 22%, complemented by a price-to-book value ratio of 5.2. Despite this valuation, Lupin trades at a discount relative to its peers’ historical averages, suggesting a favourable pricing dynamic in the mid-cap pharmaceutical space.

Institutional investors hold a substantial 47.08% stake in Lupin Ltd., reflecting confidence from entities with extensive analytical resources and a long-term investment horizon. This level of institutional ownership often correlates with enhanced stock stability and liquidity.

Market Recognition and Rankings

Lupin Ltd. is distinguished among the top 1% of companies rated by MarketsMojo across a universe of over 4,000 stocks. It holds a Mojo Score of 78.0 and a current Mojo Grade of Buy, recently adjusted from a Strong Buy on 16 Feb 2026. The company ranks 10th among mid-cap stocks and 45th across the entire market, underscoring its strong positioning within its sector and market capitalisation segment.

Its market cap grade is 2, indicating a solid mid-cap status with considerable growth potential and market presence. The stock’s day change of 1.16% today further highlights its positive momentum relative to broader market movements.

Technical Strength and Momentum Indicators

The stock’s position above all major moving averages is a strong technical signal. Trading above the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages indicates sustained buying interest and a positive trend across short, medium, and long-term horizons. This technical strength is reinforced by the stock’s recent consecutive gains and outperformance relative to its sector.

Such momentum is often indicative of underlying confidence in the company’s earnings quality and growth prospects, as reflected in its improving profitability metrics and consistent sales growth. The stock’s PEG ratio of 0.3 further suggests that earnings growth is outpacing the stock price appreciation, a factor that can attract value-conscious investors.

While the broader market remains cautious with the Sensex trading below its 50-day moving average, Lupin’s ability to chart a new 52-week high highlights its resilience and leadership within the Pharmaceuticals & Biotechnology sector.

Summary of Key Financial Highlights

To summarise, Lupin Ltd.’s recent milestone of reaching Rs.2261.95 as its 52-week high is supported by:

• Annual net sales growth of 11.42%
• Operating profit margin of 33.60%
• ROCE at 22.22% for the half-year
• Quarterly PBT less other income at Rs.1,833.91 crores, up 43.6%
• Record quarterly net sales of Rs.7,167.52 crores
• ROE of 22% with a price-to-book value of 5.2
• Institutional holdings at 47.08%
• Mojo Score of 78.0 and a Buy grade from MarketsMojo

These factors collectively underpin the stock’s strong performance and its ability to sustain upward momentum amid a competitive market environment.

Conclusion

Lupin Ltd.’s achievement of a new 52-week high at Rs.2261.95 marks a significant milestone reflecting the company’s solid financial footing and positive market sentiment. Supported by consistent sales growth, improving profitability, and strong technical indicators, the stock has demonstrated resilience and leadership within the Pharmaceuticals & Biotechnology sector. Its relative outperformance against the Sensex and sector peers further emphasises the strength of this rally.

As Lupin continues to trade above key moving averages and maintain robust institutional support, the stock’s recent gains highlight a period of sustained momentum and confidence in its business fundamentals.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →